• Vericel Corp VCEL.OQ reported quarterly adjusted earnings of 10 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of 38 cents. The mean expectation of seven analysts for the quarter was for a loss of one cent per share. Wall Street expected results to range from 31 cents to 3 cents per share.

• Revenue rose 23.3% to $92.92 million from a year ago; analysts expected $64.56 million.

• Vericel Corp's reported EPS for the quarter was 10 cents​.

• The company reported quarterly net income of $23.24 million.

• Vericel Corp shares had risen by 3.0% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Vericel Corp is $56.50, about 34.4% above its last closing price of $37.09

This summary was machine generated from LSEG data February 26 at 02:50 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)